| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.49(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
174,646 |
582,159 |
708,287 |
1,344,542 |
| Total Sell Value |
$1,434,443 |
$3,799,019 |
$4,251,315 |
$4,881,053 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
14 |
32 |
54 |
97 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raab Michael |
President & CEO |
• • – |
2024-04-15 |
4 |
AS |
$7.06 |
$52,924 |
D/D |
(7,500) |
1,310,933 |
|
-6% |
|
| Raab Michael |
President & CEO |
• • – |
2024-04-01 |
4 |
AS |
$7.31 |
$11,097 |
D/D |
(1,518) |
1,318,433 |
|
-13% |
|
| Kelliher Mike |
See Remarks |
• • – |
2024-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
160,000 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• • – |
2024-03-20 |
4 |
AS |
$7.73 |
$664,978 |
D/D |
(86,000) |
312,993 |
|
-18% |
|
| Blanks Robert |
See Remarks |
• • – |
2024-03-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
367,186 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• • – |
2024-02-26 |
4 |
S |
$9.20 |
$47,684 |
I/I |
(5,183) |
175,936 |
|
32% |
|
| Williams Laura A |
Chief Medical Officer |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$42,008 |
D/D |
(4,803) |
380,138 |
|
26% |
|
| Grammer Elizabeth A |
See Remarks |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$38,764 |
D/D |
(4,432) |
398,993 |
|
26% |
|
| Rosenbaum David P. |
Chief Development Officer |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$20,064 |
I/I |
(2,294) |
181,119 |
|
26% |
|
| Rosenbaum David P. |
Chief Development Officer |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$43,880 |
D/D |
(5,017) |
378,985 |
|
26% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$60,594 |
D/D |
(6,928) |
452,795 |
|
26% |
|
| Blanks Robert |
See Remarks |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$43,880 |
D/D |
(5,017) |
368,186 |
|
26% |
|
| Raab Michael |
President & CEO |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$200,439 |
D/D |
(22,917) |
1,319,951 |
|
26% |
|
| Felsch Robert Ora |
See Remarks |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$20,571 |
D/D |
(2,352) |
184,834 |
|
26% |
|
| Renz Justin A |
Chief Financial Officer |
• • – |
2024-02-20 |
4 |
S |
$8.75 |
$46,714 |
D/D |
(5,341) |
304,835 |
|
26% |
|
| Rosenbaum David P. |
Chief Development Officer |
• • – |
2024-02-08 |
4 |
AS |
$9.18 |
$140,846 |
D/D |
(15,344) |
384,002 |
|
-31% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
118,750 |
384,941 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
475,000 |
1,342,868 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
127,750 |
403,425 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
I/I |
70,120 |
183,413 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
112,750 |
399,346 |
|
- |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
127,750 |
310,176 |
|
- |
|
| Blanks Robert |
See Remarks |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
112,750 |
373,203 |
|
- |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
112,750 |
459,723 |
|
- |
|
| Felsch Robert Ora |
See Remarks |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
70,120 |
187,186 |
|
- |
|
538 Records found
|
|
Page 1 of 22 |
|
|
0.11 (1.74%) 
